Merrill Lynch Downgrades Barr Pharmaceuticals (BRL) to Neutral
More News related to BRL
- Matrix USA Rating Changes 5/16
- Cowen upgrades Barr Pharmaceuticals (BRL) to Outperform
- Barr Pharmaceuticals (BRL) Receives FDA Approval for Generic Yasmin
- Barr Announces Approval of Generic Yasmin(R)
- Matrix USA Rating Changes 5/9
More News related to Downgrades
- DA Davidson Downgrades Preferred Bank (PFBC) to Neutral; $10 PT
- CL King Downgrades Audiovox (VOXX) to Accumulate
- FTN Midwest Downgrades Savings & Loans
- Matrix USA Rating Changes 5/16
- Caris & Co Downgrades Response Genetics (RGDX) to Above Average
Merrill Lynch downgrades Barr Pharmaceuticals Inc. (NYSE: BRL) from Buy to Neutral.
NOTE: BRL is down nearly 24% today after disappointing qtr results and guidance
Related Categories
DowngradesStocks Mentioned
+0.03Related Entities
Comments
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
brl
gary natar on May 8, 2008 02:02 PMgreat timing merrill lynch sAVED PEOPLE A FORTUNE BY DOWNGRADING AFTER THE FALL